Atria Investments Inc Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Atria Investments Inc acquired a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm acquired 18,928 shares of the company’s stock, valued at approximately $364,000.

Several other large investors have also recently added to or reduced their stakes in SNDX. Northwestern Mutual Wealth Management Co. bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth $27,000. Values First Advisors Inc. bought a new position in shares of Syndax Pharmaceuticals in the third quarter worth $30,000. nVerses Capital LLC bought a new position in shares of Syndax Pharmaceuticals in the second quarter worth $33,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after buying an additional 541 shares in the last quarter. Finally, Quarry LP boosted its stake in Syndax Pharmaceuticals by 75.0% in the second quarter. Quarry LP now owns 6,125 shares of the company’s stock valued at $126,000 after buying an additional 2,625 shares in the last quarter.

Wall Street Analysts Forecast Growth

SNDX has been the topic of several research analyst reports. Barclays raised their price objective on Syndax Pharmaceuticals from $32.00 to $33.00 and gave the company an “overweight” rating in a research note on Thursday, August 15th. The Goldman Sachs Group lifted their price target on Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Bank of America lifted their price target on Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. lifted their price objective on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, HC Wainwright lifted their target price on Syndax Pharmaceuticals from $49.00 to $51.00 and gave the stock a “buy” rating in a report on Monday. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $37.64.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $15.60 on Friday. The stock’s 50 day simple moving average is $18.71 and its two-hundred day simple moving average is $20.08. The stock has a market cap of $1.33 billion, a price-to-earnings ratio of -4.30 and a beta of 0.92. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $15.00 and a fifty-two week high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, topping analysts’ consensus estimates of ($1.13) by $0.15. The company had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the prior year, the firm earned ($0.73) earnings per share. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -3.69 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).